Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-Targeted CAR-T in B Cell Malignancies
NCT02954445Phase 2Unknown
- Sponsor
- Southwest Health System
- Start
- Oct 2016
- Primary completion
- Oct 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-BCMA-CAR-transduced T cells in B-cell leukemia (BCL), B cell lymphoma and multiple myeloma (MM), sponsored by Southwest Health System. Primary endpoint: Adverse Events That Are Related to Treatment at 3 years. Status: unknown.
02
Drugs
anti-BCMA-CAR-transduced T cells
03
Conditions
B-cell leukemia (BCL)B cell lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT02954445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954445.